ARTA
NVIV

A.R.T. Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

A.R.T. Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3
Closed -$78K – 1869
2017
Q3 		$78K Buy
+3
New +$92.2K ﹤0.01% 1229

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

A.R.T. Advisors's NVIV Position: Q4 2017 in Review

A.R.T. Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2017, closing a stake of 3 shares — an estimated $78K sold.

A.R.T. Advisors first reported a position in NVIV in Q3 2017 and held it in 1 quarter. The position peaked at $78K in Q3 2017. 28 funds tracked by Wall St. Rank hold NVIV as of Q4 2017.

  • A.R.T. Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 3 InVivo Therapeutics Holdings Corp shares in Q4 2017, an estimated $78K.
  • A.R.T. Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q3 2017 and held it in 1 quarter.
  • A.R.T. Advisors's InVivo Therapeutics Holdings Corp position peaked at $78K in Q3 2017.
  • 28 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2017.

Based on A.R.T. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.